Medicinal products — List of marketing authorisations granted by the EEA EFTA States for the first half of 2014
Date: 2015-09-17
Institutions: Standing Committee of the EFTA States
Subjects: EFTA countries, free movement of goods, market approval, medicinal product








C_2015306EN.01000601.xml










17.9.2015   


EN


Official Journal of the European Union


C 306/6





Medicinal products — List of marketing authorisations granted by the EEA EFTA States for the first half of 2014
(2015/C 306/08)

Subcommittee I on the free movement of goods


To be noted by the EEA Joint Committee

With reference to EEA Joint Committee Decision No 74/1999 of 28 May 1999, the EEA Joint Committee is invited to note the following lists concerning marketing authorisations for medicinal products for the period 1 January – 30 June 2014, at their meeting on 12 December 2014:







Annex I



List of new marketing authorisations





Annex II



List of renewed marketing authorisations





Annex III



List of extended marketing authorisations





Annex IV



List of withdrawn marketing authorisations





Annex V



List of suspended marketing authorisations






ANNEX I
List of new marketing authorisations
The following marketing authorisations have been granted in the EEA EFTA States during the period 1 January – 30 June 2014:








EU Number


Product


Country


Date of authorisation




EU/1/06/361


Luminity


Iceland


5.6.2014




EU/1/06/367


Diacomit


Liechtenstein


28.2.2014




EU/1/12/767


Nimenrix


Liechtenstein


30.6.2014




EU/1/13/834


Zoledronic Acid Accord


Iceland


7.2.2014




EU/1/13/834


Zoledronic acid Accord


Liechtenstein


28.2.2014




EU/1/13/834


Zoledronic acid Accord


Norway


29.1.2014




EU/1/13/837


Tecfidera


Iceland


11.2.2014




EU/1/13/837


Tecfidera


Liechtenstein


28.2.2014




EU/1/13/837


Tecfidera


Norway


5.2.2014




EU/1/13/856


Lonquex


Liechtenstein


30.4.2014




EU/1/13/875


Deltyba


Iceland


23.5.2014




EU/1/13/875


Deltyba


Liechtenstein


30.6.2014




EU/1/13/875


Deltyba


Norway


9.5.2014




EU/1/13/887


Fluenz Tetra


Iceland


3.1.2014




EU/1/13/887


Fluenz Tetra


Liechtenstein


28.2.2014




EU/1/13/887


Fluenz Tetra


Norway


9.1.2014




EU/1/13/889


Levetiracetam Hospira


Iceland


15.1.2014




EU/1/13/889


Levetiracetam Hospira


Liechtenstein


28.2.2014




EU/1/13/889


Levetiracetam Hospira


Norway


21.1.2014




EU/1/13/890


Cometriq


Iceland


8.4.2014




EU/1/13/890


Cometriq


Liechtenstein


30.4.2014




EU/1/13/890


Cometriq


Norway


11.4.2014




EU/1/13/891


Brintellix


Iceland


13.1.2014




EU/1/13/891


Brintellix


Liechtenstein


28.2.2014




EU/1/13/891


Brintellix


Norway


17.1.2014




EU/1/13/892


Tivicay


Iceland


6.2.2014




EU/1/13/892


Tivicay


Liechtenstein


28.2.2014




EU/1/13/892


Tivicay


Norway


28.1.2014




EU/1/13/893


Opsumit


Iceland


14.1.2014




EU/1/13/893


Opsumit


Norway


17.1.2014




EU/1/13/894


Sovaldi


Iceland


6.2.2014




EU/1/13/894


Sovaldi


Liechtenstein


28.2.2014




EU/1/13/894


Sovaldi


Norway


29.1.2014




EU/1/13/895


Cholic acid FGK


Iceland


15.4.2014




EU/1/13/895


Cholic Acid FGK


Liechtenstein


30.4.2014




EU/1/13/895


Kolsyre FGK


Norway


28.4.2014




EU/1/13/896


Para-aminosalicylic acid Lucane


Iceland


7.5.2014




EU/1/13/896


Para-aminosalicylic acid Lucane


Liechtenstein


30.4.2014




EU/1/13/896


Granupas


Norway


13.5.2014




EU/1/13/898


Anoro


Liechtenstein


30.6.2014




EU/1/13/899


Laventair


Liechtenstein


30.6.2014




EU/1/13/900


Xigduo


Iceland


6.2.2014




EU/1/13/900


Xigduo


Liechtenstein


28.2.2014




EU/1/13/900


Xigduo


Norway


28.1.2014




EU/1/13/901


SIRTURO


Iceland


4.4.2014




EU/1/13/901


Sirturo


Liechtenstein


30.4.2014




EU/1/13/901


Sirturo


Norway


14.3.2014




EU/1/13/904


Mirvaso


Iceland


20.3.2014




EU/1/13/904


Mirvaso


Liechtenstein


28.2.2014




EU/1/13/904


Mirvaso


Norway


17.3.2014




EU/1/13/905


IZBA


Iceland


18.3.2014




EU/1/13/905


Izba


Liechtenstein


28.2.2014




EU/1/13/905


Izba


Norway


17.3.2014




EU/1/13/906


Neuraceq


Iceland


20.3.2014




EU/1/13/906


Neuraceq


Liechtenstein


28.2.2014




EU/1/13/906


Neuraceq


Norway


24.3.2014




EU/1/13/907


Adempas


Iceland


8.4.2014




EU/1/13/907


Adempas


Liechtenstein


30.4.2014




EU/1/13/907


Adempas


Norway


7.4.2014




EU/1/13/908


Eperzan


Iceland


9.4.2014




EU/1/13/908


Eperzan


Liechtenstein


30.4.2014




EU/1/13/908


Eperzan


Norway


15.4.2014




EU/1/13/909


Bemfola


Iceland


14.4.2014




EU/1/13/909


Bemfola


Liechtenstein


30.4.2014




EU/1/13/909


Bemfola


Norway


25.4.2014




EU/1/14/898


ANORO


Iceland


27.5.2014




EU/1/14/898


Anoro


Norway


28.5.2014




EU/1/14/899


Laventair


Iceland


27.5.2014




EU/1/14/899


Laventair


Norway


4.6.2014




EU/1/14/911


Rivastigmine 3M Health Care Ltd.


Iceland


14.4.2014




EU/1/14/911


Rivastigmin 3M Health Care Ltd.


Liechtenstein


30.4.2014




EU/1/14/911


Rivastigmine 3M Health Care Ltd.


Norway


14.4.2014




EU/1/14/912


Zoledronic acid Teva Generics


Iceland


10.4.2014




EU/1/14/912


Zoledronic acid Teva Generics


Liechtenstein


30.4.2014




EU/1/14/912


Zoledronic acid Teva Generics


Norway


15.4.2014




EU/1/14/913


Latuda


Iceland


8.4.2014




EU/1/14/913


Latuda


Liechtenstein


30.4.2014




EU/1/14/913


Latuda


Norway


8.4.2014




EU/1/14/914


Vimizim


Iceland


23.5.2014




EU/1/14/914


Vimizim


Liechtenstein


30.6.2014




EU/1/14/914


Vimizim


Norway


23.5.2014




EU/1/14/915


Ebilfumin


Iceland


5.6.2014




EU/1/14/915


Ebilfumin


Liechtenstein


30.6.2014




EU/1/14/915


Ebilfumin


Norway


18.6.2014




EU/1/14/916


Pregabalin Pfizer


Iceland


7.5.2014




EU/1/14/916


Pregabalin Pfizer


Liechtenstein


30.4.2014




EU/1/14/916


Pregabalin Pfizer


Norway


13.5.2014




EU/1/14/917


Ulunar Breezhaler


Liechtenstein


30.6.2014




EU/1/14/917


Ulunar Breezhaler


Norway


21.5.2014




EU/1/14/918


Vokanamet


Iceland


12.5.2014




EU/1/14/918


Vokanamet


Liechtenstein


30.4.2014




EU/1/14/918


Vokanamet


Norway


29.4.2014




EU/1/14/919


Hemangiol


Iceland


12.5.2014




EU/1/14/919


Hemangiol


Liechtenstein


30.4.2014




EU/1/14/919


Hemangiol


Norway


8.5.2014




EU/1/14/920


DuoResp Spiromax


Iceland


22.5.2014




EU/1/14/920


DuoResp Spiromax


Liechtenstein


30.6.2014




EU/1/14/920


DuoResp Spiromax


Norway


22.5.2014




EU/1/14/921


BiResp Spiromax


Iceland


23.5.2014




EU/1/14/921


BiResp Spiromax


Liechtenstein


30.6.2014




EU/1/14/921


BiResp Spiromax


Norway


15.5.2014




EU/1/14/922


Incruse


Iceland


22.5.2014




EU/1/14/922


Incruse


Liechtenstein


30.6.2014




EU/1/14/922


Incruse


Norway


22.5.2014




EU/1/14/923


Entyvio


Iceland


5.6.2014




EU/1/14/923


Entyvio


Liechtenstein


30.6.2014




EU/1/14/923


Entyvio


Norway


17.6.2014




EU/1/14/924


OLYSIO


Iceland


5.6.2014




EU/1/14/924


OLYSIO


Liechtenstein


30.6.2014




EU/1/14/924


Olysio


Norway


23.5.2014




EU/1/14/928


Sylvant


Iceland


5.6.2014




EU/1/14/928


Sylvant


Liechtenstein


30.6.2014




EU/1/14/928


Sylvant


Norway


19.6.2014




EU/1/14/929


Revinty Ellipta


Iceland


26.5.2014




EU/1/14/929


Revinty Ellipta


Liechtenstein


30.6.2014




EU/1/14/929


Revinty Ellipta


Norway


15.5.2014




EU/1/14/930


Jardiance


Iceland


5.6.2014




EU/1/14/930


Jardiance


Liechtenstein


30.6.2014




EU/1/14/930


Jardiance


Norway


28.5.2014




EU/2/09/096


Leucogen


Liechtenstein


30.6.2014




EU/2/09/103


Respiporc Flu3


Norway


13.2.2014




EU/2/12/138


RevitaCAM


Liechtenstein


30.4.2014




EU/2/12/140


Poulvac E.coli


Norway


7.4.2014




EU/2/13/151


Equilis West Nile


Norway


7.4.2014




EU/2/13/153


Aftovaxpur Doe


Norway


29.1.2014




EU/2/13/154


Apoquel


Norway


21.1.2014




EU/2/13/155


Trifexis


Norway


4.4.2014




EU/2/13/156


Vectra 3D


Norway


4.4.2014




EU/2/13/157


Broadline


Norway


24.3.2014




EU/2/13/158


Bravecto


Iceland


28.2.2014




EU/2/13/158


Bravecto


Liechtenstein


28.2.2014




EU/2/13/158


Bravecto


Norway


21.3.2014




EU/2/13/159


NexGard


Iceland


28.2.2014




EU/2/13/159


NexGard


Liechtenstein


28.2.2014




EU/2/13/159


NexGard


Norway


4.4.2014




EU/2/13/160


Fungitraxx


Iceland


9.4.2014




EU/2/13/160


Fungitraxx


Liechtenstein


30.4.2014




EU/2/13/160


Fungitraxx


Norway


15.4.2014




EU/2/14/161


Equisolon


Iceland


9.4.2014




EU/2/14/161


Equisolon


Liechtenstein


30.4.2014




EU/2/14/161


Equisolon


Norway


15.4.2014




EU/2/14/162


Parvoduk


Iceland


9.5.2014




EU/2/14/162


Parvoduk


Norway


6.6.2014




EU/2/14/163


Versican Plus DHPPi/L4R


Iceland


6.6.2014




EU/2/14/164


Versican Plus DHPPi/L4


Iceland


6.6.2014




EU/2/14/164


Versican Plus DHPPi/L4


Liechtenstein


30.6.2014




EU/2/14/165


Vectra Felis


Iceland


18.6.2014




EU/2/14/165


Vectra Felis


Liechtenstein


30.6.2014







ANNEX II
List of renewed marketing authorisations
The following marketing authorisations have been renewed in the EEA EFTA States during the period 1 January – 30 June 2014:








EU Number


Product


Country


Date of authorisation




EU/1/03/265


Bonviva


Iceland


9.1.2014




EU/1/03/265


Bonviva


Norway


16.1.2014




EU/1/03/265


Bonviva


Liechtenstein


28.2.2014




EU/1/03/271


Advate


Iceland


15.1.2014




EU/1/03/271


Advate


Norway


17.1.2014




EU/1/03/271


Advate


Liechtenstein


28.2.2014




EU/1/04/274


Velcade


Norway


30.1.2014




EU/1/04/274


Velcade


Iceland


5.2.2014




EU/1/04/287


Osseor


Norway


18.6.2014




EU/1/04/287


Osseor


Liechtenstein


30.6.2014




EU/1/04/288


Protelos


Norway


18.6.2014




EU/1/04/288


Protelos


Liechtenstein


30.6.2014




EU/1/04/289


Angiox


Liechtenstein


30.6.2014




EU/1/06/367


Diacomit


Norway


17.1.2014




EU/1/06/367


Diacomit


Iceland


15.1.2014




EU/1/07/423


Vectibix


Liechtenstein


28.2.2014




EU/1/07/423


Vectibix


Norway


17.3.2014




EU/1/07/423


Vectibix


Iceland


17.3.2014




EU/1/07/436


Isentress


Norway


22.5.2014




EU/1/07/436


Isentress


Iceland


26.5.2014




EU/1/07/436


Isentress


Liechtenstein


30.6.2014




EU/1/07/440


Tyverb


Iceland


19.3.2014




EU/1/07/440


Tyverb


Norway


19.3.2014




EU/1/07/440


Tyverb


Liechtenstein


30.4.2014




EU/1/08/497


Nplate


Iceland


14.1.2014




EU/1/08/497


Nplate


Norway


17.1.2014




EU/1/08/497


Nplate


Liechtenstein


28.2.2014




EU/1/08/501


Ixiaro


Iceland


18.3.2014




EU/1/08/501


Ixiaro


Norway


25.3.2014




EU/1/08/501


Ixiaro


Liechtenstein


30.4.2014




EU/1/08/502


Mepact


Iceland


13.1.2014




EU/1/08/502


Mepact


Norway


16.1.2014




EU/1/08/502


Mepact


Liechtenstein


28.2.2014




EU/1/09/508


Synflorix


Liechtenstein


28.2.2014




EU/1/09/508


Synflorix


Iceland


18.3.2014




EU/1/09/508


Synflorix


Norway


24.3.2014




EU/1/09/509


Ribavirin Teva


Norway


29.1.2014




EU/1/09/509


Ribavirin Teva


Iceland


6.2.2014




EU/1/09/509


Ribavirin Teva


Liechtenstein


28.2.2014




EU/1/09/510


Fertavid


Liechtenstein


28.2.2014




EU/1/09/510


Fertavid


Norway


17.3.2014




EU/1/09/510


Fertavid


Iceland


18.3.2014




EU/1/09/511


Conbriza


Norway


17.3.2014




EU/1/09/512


Removab


Iceland


10.1.2014




EU/1/09/512


Removab


Norway


20.1.2014




EU/1/09/512


Removab


Liechtenstein


28.2.2014




EU/1/09/514


Zebinix


Norway


3.2.2014




EU/1/09/514


Zebinix


Iceland


5.2.2014




EU/1/09/514


Zebinix


Liechtenstein


28.2.2014




EU/1/09/515


CONTROLOC Control


Liechtenstein


28.2.2014




EU/1/09/515


CONTROLOC Control


Iceland


18.3.2014




EU/1/09/515


Controloc Control


Norway


20.3.2014




EU/1/09/516


SOMAC Control


Liechtenstein


28.2.2014




EU/1/09/516


SOMAC Control


Iceland


18.3.2014




EU/1/09/516


Somac Control


Norway


20.3.2014




EU/1/09/517


PANTOZOL Control


Liechtenstein


28.2.2014




EU/1/09/517


PANTOZOL Control


Iceland


18.3.2014




EU/1/09/517


Pantozol Control


Norway


20.3.2014




EU/1/09/518


PANTECTA Control


Liechtenstein


28.2.2014




EU/1/09/518


PANTECTA Control


Iceland


18.3.2014




EU/1/09/518


Pantecta Control


Norway


20.3.2014




EU/1/09/519


PANTOLOC Control


Liechtenstein


28.2.2014




EU/1/09/519


PANTOLOC Control


Iceland


18.3.2014




EU/1/09/519


Pantoloc Control


Norway


20.3.2014




EU/1/09/521


Renvela


Iceland


10.4.2014




EU/1/09/521


Renvela


Norway


23.4.2014




EU/1/09/521


Renvela


Liechtenstein


30.4.2014




EU/1/09/522


ellaOne


Iceland


10.4.2014




EU/1/09/522


ellaOne


Norway


25.4.2014




EU/1/09/522


ellaOne


Liechtenstein


30.4.2014




EU/1/09/523


Modigraf


Liechtenstein


28.2.2014




EU/1/09/523


Modigraf


Iceland


12.3.2014




EU/1/09/523


Modigraf


Norway


17.3.2014




EU/1/09/524


Qutenza


Liechtenstein


30.4.2014




EU/1/09/524


Qutenza


Norway


9.5.2014




EU/1/09/524


Qutenza


Iceland


14.5.2014




EU/1/09/525


Nimvastid


Norway


29.1.2014




EU/1/09/525


Nimvastid


Iceland


5.2.2014




EU/1/09/525


Nimvastid


Liechtenstein


28.2.2014




EU/1/09/526


Iressa


Iceland


9.5.2014




EU/1/09/526


Iressa


Norway


20.5.2014




EU/1/09/526


Iressa


Liechtenstein


30.6.2014




EU/1/09/527


Ribavirin Teva Pharma BV


Norway


29.1.2014




EU/1/09/527


Ribavirin Teva Pharma B.V.


Iceland


6.2.2014




EU/1/09/528


Peyona


Norway


17.3.2014




EU/1/09/528


Peyona


Iceland


19.3.2014




EU/1/09/528


Peyona


Liechtenstein


30.4.2014




EU/1/09/529


Victoza


Norway


25.4.2014




EU/1/09/529


Victoza


Liechtenstein


30.4.2014




EU/1/09/529


Victoza


Iceland


9.5.2014




EU/1/09/530


Repaglinide Teva


Liechtenstein


30.6.2014




EU/1/09/531


Instanyl


Norway


29.4.2014




EU/1/09/531


Instanyl


Liechtenstein


30.4.2014




EU/1/09/531


Instanyl


Iceland


13.5.2014




EU/1/09/532


Clopidogrel Acino


Iceland


10.4.2014




EU/1/09/532


Clopidogrel Acino


Norway


11.4.2014




EU/1/09/532


Clopidogrel Acino


Liechtenstein


30.4.2014




EU/1/09/533


Vedrop


Norway


9.5.2014




EU/1/09/533


Vedrop


Iceland


22.5.2014




EU/1/09/535


Grepid


Norway


28.4.2014




EU/1/09/535


Grepid


Liechtenstein


30.4.2014




EU/1/09/535


Grepid


Iceland


9.5.2014




EU/1/09/536


Topotecan Actavis


Iceland


20.6.2014




EU/1/09/536


Topotecan Actavis


Norway


25.6.2014




EU/1/09/536


Topotecan Actavis


Liechtenstein


30.6.2014




EU/1/09/537


Mozobil


Norway


28.4.2014




EU/1/09/537


Mozobil


Liechtenstein


30.4.2014




EU/1/09/537


Mozobil


Iceland


9.5.2014




EU/1/09/538


Afinitor


Iceland


6.6.2014




EU/1/09/538


Afinitor


Norway


18.6.2014




EU/1/09/539


Samsca


Liechtenstein


30.6.2014




EU/1/09/540


Clopidogrel Teva


Norway


26.5.2014




EU/1/09/540


Clopidogrel Teva


Iceland


6.6.2014




EU/1/09/540


Clopidogrel Teva


Liechtenstein


30.6.2014




EU/1/09/541


Clopidogrel ratiopharm GmbH


Norway


3.6.2014




EU/1/09/541


Clopidogrel ratiopharm GmbH


Iceland


6.6.2014




EU/1/09/541


Clopidogrel ratiopharm GmbH


Liechtenstein


30.6.2014




EU/1/09/544


Cimzia


Iceland


6.6.2014




EU/1/09/544


Cimzia


Norway


18.6.2014




EU/1/09/544


Cimzia


Liechtenstein


30.6.2014




EU/1/09/546


Simponi


Liechtenstein


30.6.2014




EU/1/09/550


Javlor


Norway


18.6.2014




EU/1/09/550


Javlor


Liechtenstein


30.6.2014




EU/1/09/551


Vizarsin


Norway


26.5.2014




EU/1/09/551


Vizarsin


Iceland


6.6.2014




EU/1/09/551


Vizarsin


Liechtenstein


30.6.2014




EU/1/09/552


Topotecan Teva


Liechtenstein


30.6.2014




EU/1/09/553


Zyllt


Iceland


26.5.2014




EU/1/09/553


Zyllt


Norway


26.5.2014




EU/1/09/553


Zyllt


Liechtenstein


30.6.2014




EU/1/09/555


Clopidogrel TAD


Liechtenstein


30.6.2014




EU/1/09/556


Clopidogrel Krka


Iceland


26.5.2014




EU/1/09/556


Clopidogrel Krka


Norway


26.5.2014




EU/1/09/556


Clopidogrel Krka


Liechtenstein


30.6.2014




EU/1/09/558


Zylagren


Norway


20.5.2014




EU/1/09/558


Zylagren


Iceland


26.5.2014




EU/1/09/558


Zylagren


Liechtenstein


30.6.2014




EU/1/09/559


Clopidogrel Mylan


Iceland


6.6.2014




EU/1/09/559


Clopidogrel Mylan


Liechtenstein


30.6.2014




EU/1/09/560


Clopidogrel dura


Iceland


6.6.2014




EU/1/09/560


Clopidogrel DURA


Liechtenstein


30.6.2014




EU/1/09/561


Clopidogrel Teva Pharma


Iceland


26.5.2014




EU/1/09/561


Clopidogrel Teva Pharma


Norway


26.5.2014




EU/1/09/561


Clopidogrel Teva Pharma


Liechtenstein


30.6.2014




EU/1/09/562


Clopidogrel Krka d.d.


Liechtenstein


30.6.2014




EU/1/09/564


Ilaris


Liechtenstein


30.6.2014




EU/1/09/571


Pandemic Influenza Vaccine H5N1 Baxter


Iceland


26.5.2014




EU/1/09/571


Pandemic influenza vaccine H5N1 Baxter


Norway


26.5.2014




EU/1/09/571


Pandemic influenza vaccine H5N1 BAXTER


Liechtenstein


30.6.2014




EU/1/09/581


Resolor


Iceland


19.6.2014




EU/1/09/581


Resolor


Liechtenstein


30.6.2014




EU/1/10/625


Arzerra


Norway


28.1.2014




EU/1/10/625


Arzerra


Iceland


12.2.2014




EU/1/10/625


Arzerra


Liechtenstein


28.2.2014




EU/1/11/699


Fampyra


Iceland


6.6.2014




EU/1/11/699


Fampyra


Norway


18.6.2014




EU/1/11/699


Fampyra


Liechtenstein


30.6.2014




EU/1/11/749


Caprelsa


Iceland


15.1.2014




EU/1/11/749


Caprelsa


Norway


20.1.2014




EU/1/11/749


Caprelsa


Liechtenstein


28.2.2014




EU/1/12/764


Pixuvri


Iceland


7.5.2014




EU/1/12/764


Pixuvri


Norway


20.5.2014




EU/1/12/764


Pixuvri


Liechtenstein


30.6.2014




EU/1/13/818


Bosulif


Liechtenstein


28.2.2014




EU/1/13/818


Bosulif


Norway


17.3.2014




EU/1/13/818


Bosulif


Iceland


17.3.2014




EU/1/99/103


ReFacto AF


Iceland


12.2.2014




EU/1/99/110


Sustiva


Liechtenstein


30.4.2014




EU/1/99/110


Sustiva


Norway


7.5.2014




EU/1/99/110


Sustiva


Iceland


14.5.2014




EU/1/99/111


Stocrin


Liechtenstein


30.4.2014




EU/1/99/111


Stocrin


Norway


7.5.2014




EU/1/99/111


Stocrin


Iceland


14.5.2014




EU/1/99/112


Ziagen


Iceland


8.4.2014




EU/1/99/112


Ziagen


Norway


15.4.2014




EU/1/99/112


Ziagen


Liechtenstein


30.4.2014




EU/1/99/114


Zeffix


Liechtenstein


30.6.2014




EU/2/04/042


Novem


Norway


14.2.2014




EU/2/04/043


Equilis StrepE


Iceland


7.5.2014




EU/2/04/043


Equilis StrepE


Liechtenstein


30.6.2014




EU/2/06/070


Meloxidyl


Norway


13.2.2014




EU/2/07/071


Slentrol


Norway


13.2.2014




EU/2/08/080


Reconcile


Norway


13.2.2014




EU/2/08/084


Trocoxil


Norway


13.2.2014




EU/2/08/085


Easotic


Norway


7.2.2014




EU/2/08/088


Acticam


Iceland


6.1.2014




EU/2/08/088


Acticam


Norway


29.1.2014




EU/2/08/088


Acticam


Liechtenstein


28.2.2014




EU/2/08/089


Onsior


Norway


17.3.2014




EU/2/08/090


Loxicom


Iceland


19.3.2014




EU/2/08/090


Loxicom


Norway


23.4.2014




EU/2/08/090


Loxicom


Liechtenstein


30.4.2014




EU/2/08/091


Porcilis PCV


Iceland


8.1.2014




EU/2/08/091


Porcilis PCV


Norway


13.2.2014




EU/2/08/092


Startvac


Liechtenstein


28.2.2014




EU/2/08/092


Startvac


Iceland


28.2.2014




EU/2/08/092


Startvac


Norway


23.4.2014




EU/2/09/094


BTVPUR AISap 8


Iceland


19.3.2014




EU/2/09/094


BTVPUR AlSap 8


Liechtenstein


30.4.2014




EU/2/09/095


Improvac


Liechtenstein


30.4.2014




EU/2/09/095


Improvac


Iceland


7.5.2014




EU/2/09/096


Leucogen


Iceland


20.6.2014




EU/2/09/097


Leucofeligen FeLV/RCP


Iceland


19.6.2014




EU/2/09/097


Leucofeligen FeLV/RCP


Liechtenstein


30.6.2014




EU/2/09/098


Melovem


Iceland


20.6.2014




EU/2/09/098


Melovem


Liechtenstein


30.6.2014




EU/2/09/099


Suvaxyn PCV


Iceland


19.6.2014




EU/2/09/099


Suvaxyn PCV


Liechtenstein


30.6.2014




EU/2/98/006


Nobilis


Norway


13.2.2014




EU/2/99/014


Stronghold


Norway


19.2.2014




EU/2/99/015


Oxyglobin


Norway


19.2.2014







ANNEX III
List of extended marketing authorisations
The following marketing authorisations have been extended in the EEA EFTA States during the period 1 January – 30 June 2014:








EU Number


Product


Country


Date of authorisation




EU/1/5/320


Noxafil


Norway


21.5.2014




EU/1/5/320/002-003


Noxafil


Iceland


14.5.2014




EU/1/08/492


RoActemra


Norway


19.5.2014




EU/1/08/492/007


RoActemra


Iceland


22.5.2014




EU/1/11/710/009-015


Votubia


Iceland


20.1.2014




EU/1/13/825


Imatinib Actavis


Norway


23.6.2014




EU/1/13/825/020-023


Imatinib Actavis


Iceland


27.6.2014




EU/1/98/067


MabThera


Norway


11.4.2014




EU/1/98/067/003


MabThera


Iceland


9.4.2014




EU/2/04/044


Aivlosin


Norway


17.3.2014




EU/2/09/098


Melovem


Norway


11.2.2014




EU/2/10/115


Comfortis


Norway


29.1.2014




EU/2/12/144


Contacera


Norway


21.3.2014




EU/2/12/144/05-006


Contacera


Iceland


12.3.2014







ANNEX IV
List of withdrawn marketing authorisations
The following marketing authorisations have been withdrawn in the EEA EFTA States during the period 1 January – 30 June 2014:








EU Number


Product


Country


Date of withdrawal




EU/1/00/153


Infanrix Penta


Iceland


22.1.2014




EU/1/06/339


Preotact


Liechtenstein


30.6.2014




EU/1/06/349


Avaglim


Iceland


21.1.2014




EU/1/06/381


Daronrix


Iceland


21.1.2014




EU/1/09/554


Clopidogrel ratiopharm


Iceland


21.1.2014




EU/1/09/554


Clopidogrel ratiopharm


Norway


11.2.2014




EU/1/10/626


Ribavirin BioPartners


Iceland


24.1.2014




EU/1/11/729


Onduarp


Liechtenstein


28.2.2014




EU/1/11/729


Onduarp


Iceland


12.3.2014




EU/1/11/729


Onduarp


Norway


27.3.2014




EU/1/96/014


Tritanrix HepB


Iceland


7.2.2014




EU/1/97/54


Viracept


Iceland


24.1.2014




EU/2/00/022


Ibaflin


Iceland


21.1.2014




EU/2/06/58


Flexicam


Liechtenstein


30.6.2014




EU/2/06/58


Flexicam


Norway


3.6.2014




EU/2/09/093


Netvax


Norway


7.1.2014







ANNEX V
List of suspended marketing authorisations
The following marketing authorisations have been suspended in the EEA EFTA States during the period 1 January – 30 June 2014:








EU-Number


Product


Country


Date of suspension




EU/1/06/361


Luminity


Liechtenstein


28.2.2014




EU/1/11/75


Vibativ


Liechtenstein


30.4.2014